Abstract
Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a considerable interindividual variation in the dose-response relationship regarding the magnitude of blood pressure reduction or the occurrence of side effects. We hypothesized that genetically determined differences in α-adrenergic receptor activity contribute to this variability in dose-response relationship.
Methods: Thirty-one single-nucleotide polymorphisms (SNPs) of the α1A, α1B, α1D adrenoreceptor (ADRA1A, ADRA1B, ADRA1D) and α2A, α2B adrenoreceptor (ADRA2A, ADRA2B) genes were genotyped in a group of 116 participants of the PRESCRIPT study. Haplotypes were constructed after determining linkage disequilibrium blocks.
Results: The ADRA1B SNP rs10515807 and the ADRA2A SNPs rs553668/rs521674 were associated with higher dosages of α-adrenergic receptor blocker (p < 0.05) and with a higher occurrence of side effects (rs10515807) (p = 0.005). Similar associations were found for haplotype block 6, which is predominantly defined by rs10515807.
Conclusions: This study suggests that genetic variability of α-adrenergic receptor genes might be associated with the clinically observed variation in beneficial and adverse therapeutic drug responses to α-adrenergic receptor blockers. Further studies in larger cohorts are needed to confirm our observations.
Original language | English |
---|---|
Article number | 896 |
Number of pages | 15 |
Journal | Biomedicines |
Volume | 10 |
Issue number | 4 |
DOIs | |
Publication status | Published - 13-Apr-2022 |
Keywords
- pheochromocytoma
- paraganglioma
- single nucleotide polymorphism
- adrenergic receptor
- alpha-adrenergic receptor blocker
- pharmacogenetics
- personalized medicine
- GENOME-WIDE ASSOCIATION
- GENETIC-VARIATION
- BLOOD-PRESSURE
- ALPHA(1B)-ADRENERGIC RECEPTOR
- ALPHA(2B)-ADRENERGIC RECEPTOR
- ALPHA-1-ADRENERGIC RECEPTOR
- FASTING GLUCOSE
- ADRA2A
- VARIANTS
- HYPERTENSION